Bayer AG NA vs Novartis: why the prices moved differently

• ▲

  FDA accepts Kerendia filing for kidney disease without diabetes The FDA accepted Bayer's application to expand Kerendia to chronic kidney disease patients without diabetes. If approved, this opens a large new patient group for a drug already growing fast, supporting future sales and profit.

  This regulatory milestone expands a key drug's market, directly boosting Bayer's growth outlook.

• ▲

  Bayer expands Canadian distribution and relaunches Alka-Seltzer Cold Bayer widened its Canadian distribution deal with Mint to include Xarelto and women's health products, and will relaunch Alka-Seltzer Plus as Alka-Seltzer Cold with value pricing. Both moves aim to reach more customers and lift consumer health sales.

  These commercial actions broaden product reach and address pricing pressure, supporting revenue growth.

• ▼

  US tariffs threaten EU pharma exports New US tariffs of 10% to 12.5% on many trading partners target pharmaceuticals, and Bayer is a major EU drug exporter. The EU trade deal is not ratified, so higher tariffs could raise costs and hurt Bayer's US sales.

  This is a real counterweight: tariffs could pressure Bayer's largest market and offset positive pipeline news.

Based on 9 stories →

• ▲

  FDA expands Kerendia to type 1 diabetes kidney disease The FDA approved Kerendia for chronic kidney disease in type 1 diabetes, its third US approval. This opens a new patient group for a drug already growing fast, supporting future sales and profit, which helps lift the shares.

  New regulatory approval expands a key drug's market, directly supporting Bayer's growth outlook.

• ▲

  Monsanto mRNA patent lawsuits against Pfizer, BioNTech, Moderna proceed A judge rejected bids to dismiss Monsanto's patent suits over mRNA technology used in COVID-19 vaccines. This keeps alive a potential new revenue stream from licensing or damages, reducing legal uncertainty and supporting the stock.

  New legal development that could bring in money and shows Bayer's patents have value.

• ▲

  FDA grants Priority Review to Lynkuet for breast cancer hot flashes The FDA accepted Bayer's application and granted Priority Review for Lynkuet to treat hot flashes in breast cancer patients on endocrine therapy. If approved, it would be the first such treatment, opening a new market and boosting growth prospects.

  New regulatory milestone for a potential first-in-class treatment, adding to Bayer's pipeline value.

• ▲

  Bayer to invest $2.2 billion in new Ohio manufacturing site Bayer plans a $2.2 billion pharmaceutical plant in Ohio, creating 600 jobs and supporting its oncology, heart, and kidney drug portfolio. This shows commitment to its largest market and long-term growth, which investors view favorably.

  New major capital investment signals confidence in future growth and US expansion.

Based on 6 stories →

• ▲

  Roundup settlement clears court hurdle A US appeals court rejected a challenge to Bayer's $7.25 billion Roundup settlement, keeping the case on track for a September 14 review. This reduces the legal cloud that has weighed on the shares for years, though final approval is still pending.

  It is the biggest single overhang on Bayer's stock and the news directly reduces that uncertainty.

• ▲

  FDA approves sevabertinib for first-line lung cancer Bayer won FDA accelerated approval for sevabertinib in first-line HER2-mutant NSCLC, based on a 75% response rate. This expands the drug's use to newly diagnosed patients, opening a larger market and supporting future sales growth.

  A new approval for a key cancer drug directly adds a new revenue opportunity and validates Bayer's pipeline.

• ▲

  Pipeline progress in cardiac imaging and atrial fibrillation Bayer's Phase III REVEAL study for a cardiac amyloidosis imaging agent met its goals, and a Phase II trial began for a new atrial fibrillation drug. Both are early but show Bayer's research engine is producing candidates beyond its current products.

  These are new clinical milestones that strengthen the long-term pipeline story investors are watching.

• ▲

  Expanded Canadian approval and biofuel partnership Canada broadened approval of LYNKUET for breast-cancer-related hot flashes, adding a new patient group. Separately, Bayer partnered with Neste to scale winter canola for biofuels, creating a new market for its seeds and crop technology.

  Both are fresh commercial expansions that add incremental revenue streams in health and agriculture.

Based on 6 stories →

• ▲

  Bayer seeks US duties on Chinese glyphosate Bayer asked Washington to impose duties on Chinese-made glyphosate, saying it is sold at artificially low prices. If successful, this would reduce competition and protect Bayer's US glyphosate business, supporting future earnings. However, US farm groups oppose the move, warning of higher costs for farmers.

  This is a new regulatory push that could directly benefit Bayer's crop science earnings by limiting cheap imports.

• ▲

  Bayer sells €3bn minority stake in contraceptives unit to Apollo Bayer sold a non-controlling stake in its long-acting reversible contraceptives business to Apollo for €3 billion. This strengthens Bayer's capital structure and financial flexibility, helping it manage bond maturities and litigation costs. Bayer keeps full operational control of the unit.

  This new deal brings in significant cash, reducing balance sheet pressure and supporting the stock.

• ▲

  Bayer partners with Kairos Pharma on prostate cancer combination Bayer will evaluate its radiopharmaceutical XOFIGO with Kairos Pharma's ENV-105 in metastatic prostate cancer. The combination aims to overcome drug resistance and could expand XOFIGO's use in a market worth up to $1.3 billion. This supports Bayer's oncology pipeline.

  This new collaboration could boost Bayer's pharmaceutical growth prospects, a positive for long-term revenue.

• ◆

  Bayer stock rallies 83% but valuation debate continues Bayer shares have surged 83% over the past year, yet valuation screens still show a discount. Bulls see the stock as 21% undervalued, while bears argue it is 45% overvalued due to ongoing litigation risks and provisions. The debate centers on whether the market is correctly pricing these risks.

  This highlights the tug-of-war between Bayer's strong rally and lingering legal concerns, giving a balanced view of what drives the stock.

Based on 6 stories →

• ▲

  Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.

  This is the single biggest new event and the main reason the stock moved sharply.

• ▲

  Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.

  It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.

• ▲

  Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.

  It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.

• ▲

  Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.

  It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

Based on 7 stories →

• ▲

  FDA approves Pluvicto for earlier prostate cancer The FDA approved Pluvicto for metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. This expands sales of an already marketed drug and strengthens Novartis's position in radioligand therapy, supporting future revenue growth.

  This is a new regulatory approval that directly expands the market for a key Novartis product.

• ▲

  FDA approves Rhapsido for chronic hives The FDA approved Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, a form of chronic hives. This adds a new approved indication for an oral drug that is also being tested in multiple sclerosis, broadening its potential sales.

  A new FDA approval that opens an additional market for a pipeline drug.

• ▲

  Novartis buys Tourmaline Bio for $1.4 billion Novartis agreed to acquire Tourmaline Bio for about $1.4 billion, adding pacibekitug, a Phase III-ready anti-inflammatory drug for heart and kidney diseases. This strengthens its cardiovascular pipeline and shows it is still investing in new science despite recent trial failures.

  A major acquisition that adds a late-stage asset and signals continued pipeline investment.

• ▲

  New licensing deal with Abogen worth up to $7.8 billion Novartis signed a licensing and option agreement with China's Abogen Biosciences for its lead mRNA cancer asset, ABO2203, worth up to $7.8 billion including $575 million upfront. This adds a new cancer candidate and shows Novartis can attract outside innovation.

  A large new deal that brings in a new pipeline asset and demonstrates deal-making ability.

Based on 11 stories →

• ▲

  Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

  These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

• ▼

  Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

  It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

• ▼

  CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

  It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

• ▲

  EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

  It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

Based on 6 stories →

• ▼

  ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

  New pipeline failure that directly adds to negative sentiment and future growth doubts.

• ▲

  Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

  New deal that shows continued pipeline investment and a small positive counterweight.

• ▲

  EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

  New regulatory win that broadens an existing product's label and provides a positive offset.

• ▼

  Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

  New details on activist pressure and balance-sheet strain that affect investor confidence.

Based on 16 stories →

• ▼

  Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

  This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

• ▼

  Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

  This is the biggest new negative event, causing a record share drop and directly impacting valuation.

• ▼

  Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

  This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

• ▲

  Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

  This is the main positive counterweight, showing pipeline strength and potential to offset losses.

Based on 7 stories →

• ▼

  CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

  A major safety setback that directly threatens a key pipeline and investor confidence.

• ▲

  Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

  The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

• ▼

  Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

  A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

• ▲

  Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

  A new partnership that supports future product lifecycles and is not already covered.

Based on 6 stories →

• ▲

  FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

  This is a new regulatory win that directly boosts Novartis's revenue outlook.

• ▲

  Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

  The earnings beat is a new event that shows the company's core business is performing better than expected.

• ▼

  Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

  This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

• ◆

  Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

  This highlights the key risk and potential reward that will drive the stock's longer-term direction.

Based on 12 stories →

• ▲

  EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

  This is a concrete regulatory win that directly adds a new approved product and potential sales.

• ▲

  Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

  This is a major strategic deal that bolsters the pipeline and signals growth investment.

• ▲

  ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

  This points to a significant pipeline opportunity that could drive future revenue.

• ▼

  UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

  This is a direct analyst opinion that could influence investor perception and relative performance.

Based on 7 stories →

• ▼

  Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

  This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

• ▲

  Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

  New clinical success expands the pipeline and boosts confidence in future revenue.

• ▲

  Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

  New positive trial data for a potential first-in-class therapy supports long-term growth.

• ▲

  Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

  New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

Based on 6 stories →